Condition
Fetal Neuroprotection
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02133573Phase 2Completed
Randomized Trial of Maternal Progesterone Therapy
NCT04401852Not ApplicableUnknownPrimary
Magnesium Sulfate for Fetal Neuroprotection
NCT03956121CompletedPrimary
Magnesium Sulfate (MgSO4) and Fetal Heart Rate (FHR) in Case of Prematurity
Showing all 3 trials